Immunogen (NASDAQ:IMGN) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a note issued to investors on Friday, Analyst Ratings Net reports. The firm currently has a $16.60 target price on the stock. Zacks‘ price target would suggest a potential upside of 8.92% from the stock’s previous close.
Immunogen (NASDAQ:IMGN) traded up 0.85% during mid-day trading on Friday, hitting $15.37. The stock had a trading volume of 303,811 shares. Immunogen has a one year low of $12.27 and a one year high of $20.25. The stock has a 50-day moving average of $14.50 and a 200-day moving average of $16.47. The company’s market cap is $1.313 billion.
Immunogen (NASDAQ:IMGN) last issued its quarterly earnings data on Friday, October 25th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.10. The company had revenue of $17.20 million for the quarter, compared to the consensus estimate of $12.10 million. During the same quarter last year, the company posted ($0.30) earnings per share. Immunogen’s revenue was up 319.5% compared to the same quarter last year.
A number of other firms have also recently commented on IMGN. Analysts at Morgan Stanley downgraded shares of Immunogen from an “equal weight” rating to an “underweight” rating in a research note to investors on Monday, November 11th. They now have a $9.50 price target on the stock. Separately, analysts at RBC Capital cut their price target on shares of Immunogen from $22.00 to $18.00 in a research note to investors on Friday, November 8th. They now have an “outperform” rating on the stock. Finally, analysts at Chardan Capital reiterated a “buy” rating on shares of Immunogen in a research note to investors on Tuesday, November 5th. They now have a $21.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $17.26.
ImmunoGen, Inc (NASDAQ:IMGN) develops targeted, antibody-based therapeutics for the treatment of cancer.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.